Evidence map›Paper›PMID 28718500›Full record

ArticleImmunology2017

Neurofilament light as an immune target for pathogenic antibodies.

Fabiola Puentes, Baukje J van der Star, Stephanie D Boomkamp, Markus Kipp, Louis Boon, Isabel Bosca, Joel Raffel, Sharmilee Gnanapavan, Paul van der Valk, Jodie Stephenson and 3 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04550455 (A Prospective Biomarker Study in Active Secondary Progressive Multiple Sclerosis), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04550455 phase4unknown statusnot on this mapstarted 2020, after this paper: background citation

A Prospective Biomarker Study in Active Secondary Progressive Multiple Sclerosis (SPMS)Subjects Treated With Cladribine Tablets

TypeinterventionalSponsorKeith Edwards, M.D.Ran2020 to 2025Enrolled30ConditionsMultiple SclerosisArmsCladribine Tablets
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Humoral response to neurofilaments and dipeptide repeats in ALS progression.Annals of clinical and translational neurology · 2021
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 5 countries.

Fabiola PuentesNeuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-3697-4726
Baukje J van der StarPathology Department, Vrije University Medical Centre, Amsterdam, The Netherlands.
Stephanie D BoomkampRegenerative Medicine Institute, School of Medicine, National University of Ireland, Galway, Ireland.
Markus KippInstitute of Neuroanatomy, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Louis BoonBioceros Holdings BV, Utrecht, The Netherlands.
Isabel BoscaNeuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Joel RaffelNeuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Sharmilee GnanapavanNeuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Paul van der ValkPathology Department, Vrije University Medical Centre, Amsterdam, The Netherlands.
Jodie StephensonNeuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Susan C BarnettInstitute of Infection, Immunity & Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
David BakerNeuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Sandra AmorNeuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Queen Mary University of London · GBVrije Universiteit Amsterdam · NLOllscoil na Gaillimhe – University of Galway · IEPolpharma Biologics (Netherlands) · NLRWTH Aachen University · DEUniversity of Glasgow · GB

Funding

National Centre for the Replacement, Refinement and Reduction of Animals in Research G0800572/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/K50032X/1
6 · The paper itself

Abstract

Antibodies to neuronal antigens are associated with many neurological diseases including paraneoplastic neurological disorders, epilepsy, amyotrophic lateral sclerosis and multiple sclerosis. Immunization with neuronal antigens such as neurofilament light (NF-L), a neuronal intermediate filament in axons, has been shown to induce neurological disease and spasticity in mice. Also, although antibodies to NF-L are widely used as surrogate biomarkers of axonal injury in amyotrophic lateral sclerosis and multiple sclerosis, it remains to be elucidated if antibodies to NF-L contribute to neurodegeneration and neurological disease. To address this, we examined the pathogenic role of antibodies directed to NF-L in vitro using spinal cord co-cultures and in vivo in experimental autoimmune encephalomyelitis (EAE) and optic neuritis animal models of multiple sclerosis. Here we show that peripheral injections of antibodies to NF-L augmented clinical signs of neurological disease in acute EAE, increased retinal ganglion cell loss in experimental optic neuritis and induced neurological signs following intracerebral injection into control mice. The pathogenicity of antibodies to NF-L was also observed in spinal cord co-cultures where axonal loss was induced. Taken together, our results reveal that as well as acting as reliable biomarkers of neuronal damage, antibodies to NF-L exacerbate neurological disease, suggesting that antibodies to NF-L generated during disease may also be pathogenic and play a role in the progression of neurodegeneration.

Indexed as

Amyotrophic Lateral SclerosisAnimalsAutoantibodiesAxonsEncephalomyelitis, Autoimmune, ExperimentalFemaleIntermediate FilamentsMaleMiceMice, TransgenicOptic NeuritisRetinal Ganglion CellsSpineAutoantibodiesantibodiesautoimmunityaxonal damageneurodegenerationneurofilament light

Identifiers

PMID28718500
PMCPMC5680069
OpenAlexW2738038152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.